Related Experiment Video
Updated: Apr 19, 2026

06:46
Collection of Alfalfa Root Exudates to Study the Impact of Di2-ethylhexyl Phthalate on Metabolite Production
Published on: June 2, 2023
2.4K
[Phthalate exposure in the neonatal intensive care unit]
C J Fischer Fumeaux1, C Stadelmann Diaw1, D Palmero2
1Service de néonatologie, département médico-chirurgical de pédiatrie, université de Lausanne, CHU Vaudois, avenue Pierre-Decker 2, CH-1011 Lausanne, Suisse.
Summary
Plasticizers like di(2-ethylhexyl)phthalate (DEHP) are concerning for infant health, especially in neonatal intensive care units. This study found DEHP in 6% of products, primarily respiratory devices, with limited labeling.
Area of Science:
- Environmental Health
- Toxicology
- Neonatal Care
Context:
- Growing concerns regarding the long-term health effects of plasticizers, particularly phthalates, on fertility.
- Di(2-ethylhexyl)phthalate (DEHP) is utilized in medical devices, posing risks to vulnerable newborns in neonatal intensive care units (NICUs).
- NICU environments present unique exposure scenarios for infants due to medical equipment.
Purpose:
- To identify, quantify, and characterize sources of di(2-ethylhexyl)phthalate (DEHP) within a neonatal intensive care unit.
- To assess the prevalence of DEHP in medical products used for neonates.
- To evaluate the availability of information regarding DEHP content on product packaging.
Summary:
- A comprehensive review of products in a NICU identified DEHP in 6% of all items and 10% of plastic items.
- Respiratory support devices were the most common source, accounting for 71% of DEHP-containing products.
- Information regarding DEHP content was largely absent from product packaging, hindering risk assessment.
Impact:
- Highlights the significant presence of DEHP in NICU environments, particularly in respiratory equipment.
- Underscores the need for improved product labeling and transparency regarding chemical content.
- Emphasizes the necessity for further research into the health impacts of early-life DEHP exposure and the development of safer alternatives.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
513
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
513
Teratogenicity
4.6K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.6K

